Panax Ginseng

Metadata

Approved Indications

Commission E (Germany)

• Approved (1991): “As a tonic for invigoration and fortification in times of fatigue and debility, for declining capacity for work and concentration, also during convalescence”
• Dosage specified: 1-2 g dried root daily, or equivalent preparations
• Duration: Treatment courses up to 3 months recommended; repeated courses are considered feasible
• The Commission E monograph established ginseng as a recognized phytotherapeutic tonic within the German regulatory framework, providing a strong foundation for its use in European herbal medicine

ESCOP

• Approved indication: “Decreased mental and physical capacities such as weakness, exhaustion, tiredness and loss of concentration, and during convalescence”
• The ESCOP monograph (revised 2023) summarizes controlled clinical studies demonstrating effects on fatigue, quality of life, cognitive and psychological functions, respiratory disease, metabolic parameters, and immunomodulatory properties
• Dosage: 0.5-2 g dried root daily, or 100-400 mg of standardized extract (equivalent to 4% ginsenosides)
• Duration: Up to 3 months

EMA/HMPC

• Category: Traditional use registration only (not well-established use)
• HMPC monograph: EMA/HMPC/321233/2012 (Panax ginseng C.A. Meyer, radix)
• Approved traditional use indication: “Traditional herbal medicinal product for symptoms of asthenia such as fatigue, weakness” — based on long-standing traditional use rather than clinical trial evidence meeting the well-established use threshold
• Preparations covered: White and red ginseng root preparations including dried and powdered root, and dry, soft, and liquid extracts
• Duration: Up to 3 months; consult a healthcare professional if symptoms persist beyond 2 weeks
• Age restriction: Adults and elderly only
• The HMPC assessment report (EMA/HMPC/321232/2012) reviewed the available clinical evidence but concluded it was insufficient for well-established use classification due to heterogeneity in preparations studied and indications assessed

Agreement/Disagreement

There is broad agreement across all three European regulatory bodies that Panax ginseng is indicated for fatigue, weakness, and declining mental and physical performance. However, there is a meaningful divergence in the strength of endorsement:

• Commission E and ESCOP both provide relatively strong endorsements, recognizing the clinical evidence base as sufficient to support the tonic indication. Both bodies specify clear dosage ranges and acknowledge the adaptogenic/tonic pharmacological basis of ginseng’s effects.
• EMA/HMPC takes a more conservative position, classifying ginseng under “traditional use” rather than “well-established use” — this reflects the HMPC’s stricter evidentiary standards and their assessment that the clinical trial evidence, while extensive, is too heterogeneous across different preparations and indications to meet the well-established threshold for any single indication.
• WHO monograph aligns more closely with Commission E and ESCOP, recognizing ginseng as a “prophylactic and restorative agent for enhancement of mental and physical capacities” with specified dosage of 0.5-2 g dried root or 100-300 mg standardized extract daily.
• This regulatory gap is notable because ginseng arguably has more clinical trial evidence than many herbs that have received well-established use status, highlighting the challenges of evaluating a multi-indication herb with diverse preparations. The central issue is that ginseng’s clinical evidence is spread across at least 8-10 distinct therapeutic indications, preventing any single indication from accumulating the concentrated body of evidence that the HMPC requires for well-established use classification.
• Health Canada has established a comprehensive Natural Health Products monograph for Panax ginseng, recognizing it as a traditional medicine for multiple indications including as an adaptogen to help with mental and physical fatigue, and to help support cognitive function.

Conditions Treated

Primary (Strong Evidence)

• Fatigue and asthenia — The most consistently supported indication across all regulatory bodies and clinical evidence. A 2023 systematic review and meta-analysis of 12 RCTs found a modest but statistically significant reduction in disease-related fatigue with ginseng supplementation (Kim et al., J Ginseng Res, 2023). Both cancer-related fatigue and general fatigue have shown response in clinical trials.
• Cognitive function (memory) — A 2024 systematic review and meta-analysis of 15 RCTs (n=671) found that ginseng has a significant positive effect on memory improvement, particularly at higher doses, though effects on overall cognition, attention, and executive function were not significant (Wang et al., Phytother Res, 2024). The Cochrane review on ginseng for cognition (Laws et al., 2012) found insufficient convincing evidence for healthy participants, but more recent meta-analyses with larger datasets have been more favorable for memory specifically.
• Glycemic regulation — A systematic review and meta-analysis of 16 RCTs found that ginseng modestly but significantly improved fasting blood glucose in both diabetic and non-diabetic populations. Korean red ginseng (200 mg/day for 8 weeks) improved glucose and insulin regulation in well-controlled type 2 diabetes in a pivotal RCT (Vuksan et al., Nutr Metab Cardiovasc Dis, 2008). Subgroup analyses also showed significant HbA1c benefit in parallel-design trials.

Secondary (Moderate Evidence)

• Immune modulation and upper respiratory infection prevention — A landmark RCT by Scaglione et al. (1996) found that 227 volunteers receiving G115 (100 mg/day for 12 weeks) alongside influenza vaccination showed significantly higher antibody titers and NK cell activity compared to placebo plus vaccination. The proprietary extract CVT-E002 (COLD-fX) at 400 mg/day for 4 months reduced the frequency and severity of upper respiratory infections in older adults in a well-designed RCT (n=783).
• Erectile dysfunction — A 2008 systematic review of 6 RCTs (n=349) of Korean red ginseng found a significant effect (RR 2.40, 95% CI 1.65-3.51). However, the more recent Cochrane systematic review (Jang et al., 2021) based on 9 studies provided a more cautious assessment, concluding ginseng may have only “trivial effects” on erectile function as measured by validated instruments, though men reported improved self-assessed ability to have intercourse.
• Physical performance enhancement — Evidence is mixed and generally does not support significant ergogenic effects. While some trials showed improved endurance and reduced exercise-related fatigue, systematic reviews have concluded the evidence is insufficient to confirm physical performance enhancement as a reliable effect.
• Quality of life and psychological well-being — Several RCTs using the G115 extract have shown improvements in quality-of-life measures, mood, and subjective well-being, though effect sizes are generally small to moderate.

Traditional Use

Traditional Chinese Medicine (TCM)

Ren Shen (ginseng root) is classified as the premier Qi tonic in TCM pharmacology, belonging to the category of “Tonic herbs for Qi Deficiency.” It is considered the strongest herb for tonifying Yuan (primary) Qi across all five Yin organs, with particular affinity for the Spleen and Lung. Key traditional indications include:

• Extreme collapse of Qi — shortness of breath, weak pulse, cold limbs, profuse sweating, organ prolapse
• Spleen and Lung Qi deficiency — fatigue, poor appetite, loose stools, chronic cough, spontaneous sweating
• Heart Qi and Blood deficiency — palpitations, anxiety, insomnia, forgetfulness, restlessness of the Shen (spirit)
• Generation of body fluids — thirst and dryness in febrile diseases or diabetes (Xiao Ke syndrome)
• Blood deficiency — through the strong tonification of Qi, ginseng indirectly generates and moves Blood

Ren Shen appears in numerous classical prescriptions including Si Jun Zi Tang (Four Gentleman Decoction), Bu Zhong Yi Qi Tang (Tonify the Middle and Augment the Qi Decoction), and Sheng Mai San (Generate the Pulse Powder).

Japanese Kampo Medicine

In Kampo, ginseng (Ninjin) features in numerous classical formulas. Ninjin-to (Ren Shen Tang) — composed of ginseng, licorice, atractylodes, and dried ginger — is used for digestive weakness, anorexia, and diarrhea with cold constitution. Ginseng is also a key component of Hochu-ekki-to (Bu Zhong Yi Qi Tang in Chinese), used for chronic fatigue and immune deficiency.

Korean Traditional Medicine

Insam (ginseng) holds a central position in Korean traditional medicine, with Korean red ginseng (Hongsam) — produced by steaming and drying the root — considered more warming and potent than white ginseng. Traditional indications parallel TCM use with emphasis on longevity, vitality, and recovery from illness. Korea has the longest continuous history of cultivated ginseng production, and the Korean Ginseng Corporation (formerly the Korean Tobacco and Ginseng Corporation) maintains rigorous quality standards for commercial red ginseng products. The 6-year cultivation cycle required for high-quality ginseng root reflects the traditional understanding that the root must mature sufficiently to accumulate therapeutic levels of ginsenosides.

Western Herbal Medicine

In the Western herbal tradition, ginseng was adopted primarily in the 20th century as an adaptogen — a concept formalized by Soviet pharmacologist Nikolai Lazarev in 1947 and further developed by Israel Brekhman in the 1960s-1970s. Western practitioners typically use ginseng for chronic fatigue states, convalescence after illness, age-related cognitive decline, and as a general tonic for elderly patients. The Western approach tends to emphasize standardized extracts (particularly G115) over traditional decoctions, and treatment is typically time-limited (8-12 weeks) rather than the more extended use patterns seen in East Asian medicine.

Mechanism of Action

Ginsenoside Pharmacology

Ginsenosides are triterpenoid saponins derived from 2,3-oxidosqualene that constitute the primary bioactive compounds in Panax ginseng. Over 150 different ginsenosides have been identified, but six — Rb1, Rb2, Rc, Rd, Re, and Rg1 — account for more than 90% of the total ginsenoside content in the root. The pharmacological activity of each ginsenoside depends on its structural class, sugar moiety positions, and the number and type of glycone groups attached at C-3, C-6, and C-20 positions.

Two broad structural classes determine primary mechanism:

• Protopanaxadiol (PPD) group (Rb1, Rb2, Rc, Rd, Rg3, Rh2): Tend to have calming, anti-inflammatory, and neuroprotective effects
• Protopanaxatriol (PPT) group (Re, Rf, Rg1, Rg2, Rh1): Tend to have stimulating, immunomodulatory, and vasoactive effects

Due to their structural similarity to steroid hormones, ginsenosides are amphiphilic molecules that can interact with and modify cell membrane properties. Some ginsenosides have been demonstrated to act as partial agonists at steroid hormone receptors, which may explain both the tonic effects and the hormonal cautions associated with long-term use.

HPA Axis Modulation (Adaptogenic Mechanism)

The adaptogenic properties of ginseng are primarily mediated through regulation of the hypothalamic-pituitary-adrenal (HPA) axis:

• Ginsenoside Rg1 normalizes HPA axis function by modulating serum corticosterone and testosterone levels and regulating glucocorticoid receptor (GR) expression in the prefrontal cortex and hippocampus. In chronic unpredictable mild stress (CUMS) models, Rg1 restored HPA axis homeostasis.
• Ginsenoside Rb1 attenuates glucocorticoid-induced neurotoxicity and reverses stress-induced decreases in hippocampal BDNF/TrkB expression while normalizing elevated plasma ACTH and corticosterone levels.
• The net effect is biphasic stress modulation: ginseng prevents both excessive cortisol secretion during acute stress and cortisol depletion during chronic stress, thereby maintaining allostatic balance.

Neuroprotection and Cognitive Enhancement

• BDNF/TrkB/CREB pathway: Ginsenoside Rb1 exerts antidepressant-like effects by upregulating BDNF expression and activating the TrkB-CREB signaling cascade in the hippocampus, promoting neuronal survival and synaptic plasticity.
• Anti-neuroinflammation: Rb1 suppresses peripheral and central (hippocampal) inflammation via inhibition of MAPK/NF-kB signaling, protecting against LPS-induced depressive behavior.
• Cholinergic enhancement: Several ginsenosides (particularly Rg1 and Rb1) modulate acetylcholinesterase activity and enhance cholinergic neurotransmission, which may underlie the memory-enhancing effects observed in clinical trials.
• Antioxidant neuroprotection: Ginsenosides Rg1 and Rg3 protect neurons from oxidative stress-induced apoptosis through upregulation of endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase).

Nitric Oxide (NO) Synthesis and Vascular Effects

• Ginsenosides Rg1 and Re stimulate endothelial nitric oxide synthase (eNOS) activity, promoting NO-dependent vasodilation
• This mechanism underlies the modest blood pressure regulatory effects and may contribute to the reported benefits in erectile dysfunction
• Rg3 has been shown to inhibit platelet aggregation through NO-mediated pathways

Immune Modulation

• NK cell activation: Ginsenosides and ginseng polysaccharides enhance natural killer cell cytotoxicity through upregulation of NF-kB pathway and increased cytokine expression (IFN-gamma, TNF-alpha, IL-2)
• Macrophage activation: Ginseng polysaccharides (ginsenan PA and PB) stimulate macrophage phagocytosis and cytokine production
• Adaptive immunity: Ginsenoside Re enhances antibody responses (IgG, IgG1, IgG2a, IgG2b) to viral antigens; G115 extract increased influenza vaccine antibody titers in a large clinical trial
• T-cell modulation: Both CD4+ and CD8+ T-cell proliferation and function are enhanced, with a bias toward Th1 immune responses

Metabolic Effects

• Insulin sensitization: Ginsenosides improve insulin sensitivity through activation of AMPK and enhancement of GLUT4 translocation in skeletal muscle
• Hepatic glucose regulation: Reduction of hepatic gluconeogenesis through modulation of PEPCK and G6Pase gene expression
• Gut microbiota interaction: Ginsenosides undergo extensive biotransformation by gut bacteria, converting PPD-type ginsenosides (Rb1, Rb2) into compound K (20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol), which has 3-5 fold greater bioavailability than parent compounds. This gut-mediated activation is a significant factor in inter-individual variability of ginseng response.

Antioxidant and Anti-inflammatory Effects

• NF-kB pathway inhibition: Multiple ginsenosides (particularly Rg3 and Rh2) suppress NF-kB-mediated inflammatory signaling, reducing production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and inflammatory mediators (COX-2, iNOS)
• Nrf2 pathway activation: Ginsenosides activate the Nrf2/ARE pathway, upregulating phase II detoxification enzymes and endogenous antioxidant defenses (heme oxygenase-1, NAD(P)H quinone oxidoreductase 1)
• Mitochondrial protection: Rb1 and Rg1 protect mitochondrial function under oxidative stress conditions, maintaining membrane potential and ATP production while reducing ROS generation
• These anti-inflammatory and antioxidant mechanisms are considered to underlie many of the diverse clinical effects of ginseng, from neuroprotection to cardiovascular benefit to immune modulation

Bioavailability Considerations

Oral bioavailability of intact ginsenosides is generally low (1-5%) due to poor intestinal absorption and extensive first-pass metabolism. The clinical effects of oral ginseng are therefore substantially dependent on gut microbiota-mediated biotransformation of ginsenosides into more bioavailable metabolites. This has important implications for inter-individual variability in clinical response and may explain inconsistencies across clinical trials. A 2025 systematic review highlighted that ginsenosides undergo biotransformation into bioactive metabolites through gut microbial action, enhancing their bioavailability by 3- to 5-fold, and that this microbiota-mediated pathway represents a critical determinant of therapeutic efficacy.

Clinical Evidence Summary

Cochrane Reviews

Key Meta-Analyses

Key Individual RCTs

Notable Methodological Considerations

Several important factors affect the interpretation of the ginseng clinical evidence base:

1. Species confusion: Many older trials do not clearly distinguish between Panax ginseng (Asian/Korean ginseng) and Panax quinquefolius (American ginseng). These are pharmacologically distinct species with different ginsenoside profiles — P. ginseng has a higher Rg1:Rb1 ratio (more stimulating), while P. quinquefolius has a higher Rb1:Rg1 ratio (more calming). The Barton 2013 cancer fatigue trial, for example, used American ginseng rather than Asian ginseng.

2. White vs. Red ginseng: The steaming process that produces red ginseng converts native ginsenosides into unique compounds (Rg3, Rk1, Rg5, Rs3) with distinct pharmacological profiles. Trials using white ginseng versus red ginseng are not directly comparable, yet meta-analyses often pool them.

3. Extract standardization variability: Even among “standardized” products, ginsenoside profiles can vary significantly depending on the source root age (typically 4-6 year old roots are used), growing conditions, harvest time, and extraction methodology. The G115 extract has the most consistent quality documentation across clinical trials.

4. Publication bias and geographic concentration: A disproportionate number of ginseng RCTs originate from South Korea and China, where there may be cultural and economic incentives favoring positive outcomes. Independent Western replication of Korean trials has been limited for some indications.

5. Short trial duration: The majority of clinical trials (approximately 67%) lasted less than 12 weeks. Given that traditional use recommends courses of 2-3 months with rest periods, the optimal treatment duration and long-term benefit profile remain inadequately characterized.

Summary of Evidence Strength by Indication

Safety Profile

Contraindications

• Hormone-sensitive conditions: Estrogen-dependent cancers (breast cancer, endometrial cancer, uterine fibroids, endometriosis) — some ginsenosides have weak estrogenic activity in vitro, and case reports have documented estrogenic effects (vaginal bleeding, mastalgia). Avoid in patients with known hormone-sensitive malignancies.
• Autoimmune conditions: Due to immune-stimulating properties (enhanced NK cell activity, T-cell proliferation, cytokine production), ginseng should be used with caution or avoided in patients with autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis, where immune activation may exacerbate the condition.
• Bleeding disorders: Ginseng may inhibit platelet aggregation; avoid in patients with active bleeding disorders or before surgery (discontinue at least 7 days prior to elective surgery).
• Uncontrolled hypertension: Although evidence is mixed, some reports associate ginseng with blood pressure elevation, particularly at high doses. Monitor blood pressure in hypertensive patients.
• Mania/psychosis: Case reports of mania induction exist; avoid in patients with bipolar disorder or active psychosis.
• Children under 18: Insufficient safety data; not recommended by HMPC.

Drug Interactions

Panax ginseng has over 100 documented potential drug interactions. The most clinically significant include:

Side Effects

Common (1-10% in clinical trials)

• Headache
• Insomnia and sleep disturbance (particularly with evening dosing or high doses)
• Gastrointestinal discomfort (nausea, diarrhea, abdominal pain)
• Nervousness and restlessness

Uncommon (<1%)

• Skin rash or allergic reactions
• Tachycardia or palpitations
• Blood pressure changes (increases or decreases)
• Mastalgia (breast pain/tenderness)
• Vaginal bleeding (postmenopausal women)
• Euphoria or mania (rare, mostly case reports)

Ginseng Abuse Syndrome

First described by Siegel (1979) in a study of 133 chronic ginseng users. Symptoms associated with high-dose, long-term use included: hypertension (17%), nervousness (25%), insomnia (20%), morning diarrhea (35%), and skin eruptions (25%). This syndrome is primarily associated with doses exceeding recommended levels and duration beyond 3 months. The original study has been criticized for methodological limitations (uncontrolled, many subjects also consumed caffeine), but it informed the recommendation to limit use to 3 months.

Overall Safety Assessment

Data from clinical trials with standardized extracts (particularly G115) indicate that adverse event rates are comparable to placebo. A 2017 systematic safety analysis of Panax ginseng in RCTs (Kim et al., J Ginseng Res) found no statistically significant difference in adverse event incidence between ginseng and placebo groups. The most commonly reported adverse events were headache and GI disturbance, with rates similar in both groups.

Pregnancy and Lactation

• Pregnancy (Category C): Panax ginseng is not recommended during pregnancy. Ginsenoside Rb1 has been found to cause developmental abnormalities in rat embryo culture (teratogenic effects in animal models), including effects on embryonic morphogenesis at concentrations achievable through oral dosing. However, a Korean cohort study (Seely et al., 2008) evaluating 88 women who used ginseng during pregnancy found no association with adverse outcomes including congenital malformations, low birth weight, or preterm delivery, creating conflicting evidence. The EMA/HMPC monograph does not approve use during pregnancy. The precautionary principle applies: avoid use, especially during the first trimester. In Traditional Chinese Medicine, Ren Shen is sometimes used cautiously during pregnancy under practitioner supervision for severe Qi deficiency, but this practice should not be extrapolated to self-medication.
• Lactation: Insufficient human data on excretion into breast milk. Not recommended during breastfeeding. The HMPC monograph does not approve use during lactation. No published studies specifically address ginsenoside transfer into breast milk or effects on nursing infants.

Clinical Dosage

Standard Dosage Table

Important Dosing Notes

• Timing: Morning or early afternoon administration preferred to avoid insomnia; avoid evening dosing
• Cycling: Traditional practice and regulatory recommendations suggest limiting continuous use to 3 months, followed by a rest period of 2-4 weeks before resuming. This practice may also help minimize the development of ginseng abuse syndrome symptoms.
• Standardization: When using commercial extracts, verify standardization to total ginsenoside content (typically 4-7% for quality products). The ginsenoside profile should be authenticated to distinguish genuine P. ginseng from adulterants or other ginseng species.
• White vs. Red ginseng: Red ginseng (steamed) contains unique ginsenosides (Rg3, Rk1, Rg5) not present in white ginseng, formed during the steaming process. Red ginseng may have different clinical effects and is traditionally considered more warming and potent.
• Inter-individual variability: Due to the dependence on gut microbiota for ginsenoside biotransformation, clinical response may vary significantly between individuals. Patients who do not respond to standard doses may benefit from fermented ginseng preparations with enhanced bioavailability.

Sources

Regulatory Documents

• German Commission E Monograph: Ginseng radix (Panax ginseng). Bundesanzeiger, 1991. Available via American Botanical Council HerbalGram.
• ESCOP Monographs: Ginseng radix (Ginseng). 2nd ed. revised. Exeter: ESCOP; 2023.
• EMA/HMPC: European Union herbal monograph on Panax ginseng C.A. Meyer, radix. EMA/HMPC/321233/2012.
• EMA/HMPC: Assessment report on Panax ginseng C.A. Meyer, radix. EMA/HMPC/321232/2012.

Cochrane Reviews

• Laws KR, Sweetnam H, Kondel TK. “Is Ginseng a cognitive enhancer? A systematic review and meta-analysis.” Cochrane (unpublished review protocol); published summary: Cochrane Evidence CD007769.
• Jang DJ et al. “Ginseng for Erectile Dysfunction: A Cochrane Systematic Review.” World J Mens Health. 2021;39(2):341-354. PMC8987140.

Meta-Analyses and Systematic Reviews

• Wang Y et al. “Effects of Ginseng on Cognitive Function: A Systematic Review and Meta-Analysis.” Phytother Res. 2024;38(12). PubMed 39474788.
• Kim YS et al. “Ginseng and Ginseng Herbal Formulas for Symptomatic Management of Fatigue: A Systematic Review and Meta-Analysis.” J Ginseng Res. 2023;47(2). PubMed 36730693.
• Bach HV et al. “Ginseng and health outcomes: an umbrella review.” Front Pharmacol. 2023;14:1069268. doi:10.3389/fphar.2023.1069268.
• Shishtar E et al. “The Effect of Ginseng (The Genus Panax) on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.” PLOS One. 2014;9(9):e107391. PMC4180277.
• Jang DJ et al. “Red ginseng for treating erectile dysfunction: a systematic review.” Br J Clin Pharmacol. 2008;66(4):444-450. PMC2561113.
• Seely D et al. “Safety and efficacy of panax ginseng during pregnancy and lactation.” J Popul Ther Clin Pharmacol. 2008;15(1):e87-e94. PubMed 18204104.
• Coon JT, Ernst E. “Panax ginseng: a systematic review of adverse effects and drug interactions.” Drug Saf. 2002;25(5):323-344. PubMed 12020172.

Key Clinical Trials

• Scaglione F et al. “Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold.” Drugs Exp Clin Res. 1996;22(2):65-72.
• Reay JL et al. “Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity.” J Psychopharmacol. 2005;19(4):357-365. PubMed 15982990.
• Kennedy DO et al. “Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults.” Physiol Behav. 2002;75(5):739-751.
• Barton DL et al. “Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2.” J Natl Cancer Inst. 2013;105(16):1230-1238. PMC3888141.
• Vuksan V et al. “Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes.” Nutr Metab Cardiovasc Dis. 2008;18(1):46-52. PubMed 16860976.
• Cho JH et al. “Effects of Panax ginseng on the improvement of Alzheimer’s disease cognitive function.” J Korean Acad Rehabil Med. 2012.
• Kim TH et al. “Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction.” Asian J Androl. 2009;11(3):356-361.

Pharmacology and Mechanism Reviews

• Attele AS et al. “Ginseng pharmacology: multiple constituents and multiple actions.” Biochem Pharmacol. 1999;58(11):1685-1693.
• Ratan ZA et al. “Pharmacological potential of ginseng and its major component ginsenosides.” J Ginseng Res. 2021;45(2):199-210.
• Zheng M et al. “Molecular signaling of ginsenosides Rb1, Rg1, and Rg3 and their mode of actions.” J Ginseng Res. 2018;42(2):122-132. PMC5926405.
• Bao L et al. “Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases.” Front Pharmacol. 2022;13:914352. PMC9201244.
• Wang J et al. “Mechanisms of Panax ginseng action as an antidepressant.” Cell Prolif. 2019;52(6):e12696.
• Kang S, Min H. “Ginseng, the ‘Immunity Boost’: The Effects of Panax ginseng on Immune System.” J Ginseng Res. 2012;36(4):354-368. PMC3659612.

Extract-Specific References

• Nocerino E et al. “The G115 standardized ginseng extract: an example for safety, efficacy, and quality of an herbal medicine.” J Ethnopharmacol. 2020;259:112949. PMC7031746.
• Coleman CI et al. “The Standardised G115 Panax ginseng C.A. Meyer Extract: A Review of its Properties and Usage.” Evid Based Integr Med. 2005;2(4):209-217.

Safety References

• Kim HJ et al. “Safety Analysis of Panax Ginseng in Randomized Clinical Trials: A Systematic Review.” Medicines (Basel). 2015;2(2):106-126. PMC5533164.
• Siegel RK. “Ginseng abuse syndrome: problems with the panacea.” JAMA. 1979;241(15):1614-1615.
• Janetzky K, Morreale AP. “Probable interaction between warfarin and ginseng.” Am J Health Syst Pharm. 1997;54(6):692-693.
• Lee YH et al. “Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction.” J Ginseng Res. 2017;41(3):356-365. PMC5517508.

Connections

• Eleuthero — Fellow adaptogen from the Araliaceae family; formerly called “Siberian ginseng” though not a true ginseng. Both share HPA axis modulating properties. Eleuthero contains eleutherosides rather than ginsenosides and has a distinct clinical profile focused on asthenia.
• Ashwagandha — Ayurvedic adaptogen with complementary mechanisms; ashwagandha acts primarily through GABAergic and withanolide-mediated pathways vs. ginseng’s ginsenoside-driven mechanisms. Both are used for fatigue and stress, but ashwagandha has stronger anxiolytic evidence while ginseng has stronger cognitive and immune evidence.
• Rhodiola — The only adaptogen with a formal EMA/HMPC monograph for stress. Rhodiola and ginseng share HPA axis modulation as a core mechanism but differ in their secondary pathways: Rhodiola emphasizes monoamine modulation and HSP70 upregulation. Some practitioners combine them for complementary adaptogenic effects.
• Ginkgo — Both are used for cognitive support but through different mechanisms: ginkgo primarily via cerebral blood flow enhancement and PAF antagonism, ginseng via BDNF/cholinergic pathways. The combination Gincosan (G115 ginseng + GK501 ginkgo) has been studied in clinical trials for cognitive enhancement.
• Bacopa — Ayurvedic nootropic herb; bacopa has stronger evidence for long-term memory consolidation (bacoside-mediated), while ginseng shows broader adaptogenic and metabolic effects in addition to cognitive benefits.